

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: GLOBAL CARE CAPITAL INC. ("Global Care" or the "Issuer").

Trading Symbol: HLTH

Number of Outstanding Listed Securities: 83,543,235 common shares were issued and outstanding as of August 31, 2020.

Date: September 4, 2020 (for the month of August 2020)

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer is a global investment company which specializes in providing early stage financing to private and public companies. The Issuer engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining significant position in early stage investment opportunities that adequately reflect the risk profile.

2. Provide a general overview and discussion of the activities of management.

During the month of August 2020, the Issuer's business and operations included general management and administrative matters.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The Issuer's portfolio company, ViraxClear, through its joint venture with Shanghai Biotechnology Devices Ltd. ("SBD") has on August 3rd, 2020, obtained confirmation of its United States Food and Drug Administration ("FDA") Facility Registration and Device Listing. The following devices have been FDA registered, with a view to supply to The US market:

KN95 Masks - ViraxClear has developed its own range of KN95, FDA Registered and CE marked masks, which may be comfortably worn for hours.

Disposable 3 Ply Masks - ViraxClear has developed its own range of FDA Registered and CE marked 3-ply disposable masks, which are particularly helpful travelling to and from work.

Infrared Thermometer - The thermometers do not require contact with a person and can swiftly measure temperature from 1cm-5cm from the forehead. These are particularly useful for use in public places like a hotel, airport, factory or office. These are battery-operated, handy and easy to use thermometers, which do not require any trained technicians. Whilst they are by no means definitively accurate in the detection of COVID-19, they are widely being used across the world to detect potential symptomatic COVID-19 carriers.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

There were no products or services discontinued during the month of August 2020.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Issuer entered into a letter of intent dated August 6th, 2020 (the "LOI"), which sets out the basic terms and conditions for the acquisition by the Issuer of all of the issued and outstanding securities in the capital of Healthview Technologies Inc. ("Healthview") in exchange for securities of Global Care (the "Transaction").

The Issuer and Healthview have entered into the LOI, which sets out certain terms and conditions pursuant to which the proposed Transaction will be completed. The terms outlined in the LOI are subject to the parties successfully entering into a definitive agreement (the "Definitive Agreement") in respect of the Transaction on or before August 30, 2020 or such other date as the Issuer and Healthview may mutually agree. The material terms of the Transaction are as follows:

- In consideration for the Transaction, Global Care will issue an aggregate of 20,000,000 common shares of Global Care (the "Consideration Shares") to Healthview shareholders at a deemed price of \$0.09 per Consideration Share and issue to Healthview warrant holders an aggregate of 10,000,000 common share purchase warrants (the "Consideration Warrants").
- Each Consideration Warrant permits the holder thereof to acquire one Global Care common share at a price equal to \$0.05 until August 5, 2021.
- There is no hold period for the Consideration Shares or the Consideration Warrants pursuant to applicable securities laws. • In addition, Global Care will issue up to an additional 20,000,000 common shares (the "Performance Shares") if and when Healthview meets certain performance milestones on or before December 31, 2021.
- 2,000,000 finders' shares will be issued to an arm's length finder in connection with the Transaction.

The Transaction is an arms-length transaction and no change in management, or the Board of Directors of Global Care is being contemplated at this time. The LOI also contemplates other material conditions precedent to the closing of the Transaction, including the completion of due diligence, compliance with all applicable regulatory requirements and receipt of all necessary regulatory,

corporate, third-party, board and shareholder approvals being obtained, including the approval of the Canadian Securities Exchange. There can be no assurance that the Transaction will be completed as proposed, or at all.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

There were no contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced, expired or were terminated during the month of August 2020.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

On August 4 2020, the Issuer closed the previously announced sale of all of the issued and outstanding shares of its wholly-owned subsidiary ReFormation Pharmaceuticals Corp. ("ReFormation") to 360 Life Sciences Corp., an arm's length party (the "Purchaser"), pursuant to the share purchase agreement between Global Care and the Purchaser signed on June 24, 2020. The Purchaser acquired all the issued and outstanding shares of ReFormation in exchange for 800,000 common shares of the Purchaser.

8. Describe the acquisition of new customers or loss of customers.

There were no acquisitions of new customers or loss of customers during the month of August 2020.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

There were no new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks during the month of August 2020.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

There were no employee hirings, terminations or lay-offs during the month of August 2020.

11. Report on any labour disputes and resolutions of those disputes if applicable.

There were no labour disputes during the month of August 2020.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

There were no legal proceedings to which the Issuer became a party to during the month of August 2020.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

There was no indebtedness incurred or repaid by the Issuer during the month of August 2020.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
N/A			

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

There were no loans to or by Related Persons during the month of August 2020.

16. Provide details of any changes in directors, officers or committee members.

There were no changes in directors, officers or committee members during the month of August 2020.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer’s Management Discussion & Analysis for the year ended June 30, 2020 (the “MD&A”) under the heading “Risk Factors”. The MD&A is available on the Issuer’s SEDAR profile at www.sedar.com. Additional trends that are likely to impact the Issuer include:

COVID-19

The outbreak of the corona virus pandemic has impacted the Issuer’s plans and activities. The Issuer may face disruption to operations, supply chain delays, travel and trade restrictions and impact on economic activity in affected countries or regions can be expected and can be difficult to quantify. Such pandemics or

diseases represent a serious threat to maintaining a skilled workforce industry and could be a major health-care challenge for the Issuer. There can be no assurance that the Issuer's personnel will not be impacted by these pandemic diseases and ultimately that the Issuer would see its workforce productivity reduced or incur increased medical costs/insurance premiums as a result of these health risks. In addition, the COVID-19 pandemic has created a dramatic slowdown in the global economy. The duration of the COVID-19 outbreak and the resultant travel restrictions, social distancing, Government response actions, business closures and business disruptions, can all have an impact on the Issuer's operations and access to capital. There can be no assurance that the Issuer will not be impacted by adverse consequences that may be brought about by the COVID-19 pandemic on global financial markets may reduce resource prices, share prices and financial liquidity and thereby that may severely limit the financing capital available.

[the balance of this page is left intentionally blank]

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: September 4, 2020.

Alexander Somjen
Name of Director or Senior
Officer

"Alexander Somjen"
Signature

President and CEO
Official Capacity

<i>Issuer Details</i> Name of Issuer	For Month End	Date of Report YY/MM/DD
Global Care Capital Inc.	August 2020	20/09/04
Issuer Address		
789 West Pender Street, Suite 810		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vancouver, B.C., V6C 1H2	(604) 687-3141	(604) 687-2038
Contact Name	Contact Position	Contact Telephone No.
Alexander Somjen	President & CEO	(604) 687-2038
Contact Email Address	Web Site Address	
asomjen@globalcarecapital.com	N/A	